Amisulpride-Induced Seizurogenic Effect: A Potential Role of Opioid Receptor-Linked Transduction Systems

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 5, 2011, Pages 310-317

  Rehni, Ashish K ^a   Singh, Thakur Gurjeet ^a   Chand, Prem ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMISULPRIDE; CETIRIZINE; CROMOGLYCATE DISODIUM; GABAPENTIN; HISTAMINE H1 RECEPTOR; NALOXONE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BODY MOVEMENT; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DRUG FATALITY; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; VISUAL ANALOG SCALE;

AMINES; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ASTHMATIC AGENTS; CROMOLYN SODIUM; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; MICE, INBRED STRAINS; NALOXONE; RECEPTORS, GABA; RECEPTORS, HISTAMINE H1; RECEPTORS, OPIOID; SEIZURES; SULPIRIDE;

MUS;

EID: 79954561570     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00655.x     Document Type: Article

References (46)

1. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
2. Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004;50:134-43.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
5. Cook CD, Rodefer JS, Picker MJ. Selective attenuation of the antinociceptive effects of μ opioids by the putative dopamine D3 agonist 7-OH-DPAT. Psychopharmacology 1999;144:239-47.
6. Kim SW, Shin IS, Kim JM, Lee SH, Lee JH, Yoon BH et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31: 1504-9.
7. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 2002;17:S9-16.
8. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 1997;43:95-103.
9. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a doubleblind, comparative study. J Affect Disord 1998;48:47-56.
10. Abbas AI, Hedlund PB, Huang X-P, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: for antidepressant actions in vivo. Psychopharmacology 2009;205:119-28.
11. Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998;137:223-32.
12. Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995;14:294-8.
13. Harry P. Acute poisoning by new psychotropic drugs. Rev Prat 1997;47:731-5.
14. Musshoff F, Kröner L, Padosch SA, Madea B. Fatal intoxication with amisulpride and presentation of organ distribution. Arch Kriminol 2005;478:158-63.
15. Chandran M, El-Shazly M. Catatonia, neuroleptics and brain damage - a case report. J Psychopharmacol 2009;23:223-6.
16. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 2003;478:155-9.
17. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res 1983;287:197-210.
18. Miura M, Saino-Saito S, Masuda M, Kobayashi K, Aosaki T. Compartment-specific modulation of GABAergic synaptic transmission by mu-opioid receptor in the mouse striatum with green fluorescent protein-expressing dopamine islands. J Neurosci 2007;27:9721-8.
19. Rehni AK, Singh I, Kumar M. Tramadol induced seizurogenic effect: a possible role of opioid dependent-GABA inhibitory pathway. Basic Clin Pharmacol Toxicol 2008;103:262-6.
20. Barke KE, Hough LB. Simultaneous measurement of opiate-induced histamine release in the periaqueductal gray and opiate antinociception: an in vivo microdialysis study. J Pharmacol Exp Ther 1993;266:934-42.
21. Zhu-Ge ZB, Zhu YY, Wu DC, Jin CL, Chen Z. Involvement of endogenous histamine in modulatory effect of morphine on seizure susceptibility in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban 2007;36:130-3.
22. Rehni AK, Singh TG, Singh N, Arora S. Tramadol-induced seizurogenic effect: a possible role of opioid-dependent histamine (H1) receptor activation-linked mechanism. Naunyn Schmiedebergs Arch Pharmacol 2010;381:11-9.
23. Saboory E, Derchansky M, Ismaili M, Jahromi SS, Brull R, Carlen PL et al. Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg 2007;105:1729-35.
24. Vohora D, Pal SN, Pillai KK. Thioperamide, a selective histamine H3 receptor antagonist, protects against PTZ-induced seizures in mice. Life Sci 2000;66:297-301.
25. Chen Z, Li WD, Zhu LJ, Shen YJ, Wei EQ. Effects of histidine, a precursor of histamine, on pentylenetetrazole-induced seizures in rats. Acta Pharmacol Sin 2002;23:361-6.
26. Yokoyama H, Onodera K, Iinuma K, Watanabe T. 2-Thiazolylethylamine, a selective histamine H1 agonist, decreases seizure susceptibility in mice. Pharmacol Biochem Behav 1994;47:503-7.
27. Hardman JG, Limbird LE, Gilman AG. (eds). In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. McGraw Hill, New York, 2001.
28. Patalano F, Ruggieri F. Sodium cromoglycate: a review. Eur Respir J 1989;6:556-60.
29. Zarrindast MR, Khalilzadeh A, Rezayat SM, Sahebgharani M, Djahanguiri B. Influence of intracerebroventricular administration of histaminergic drugs on morphine state-dependent memory in the step-down passive avoidance test. Pharmacology 2005; 74:106-12.
30. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11:S133-53.
31. Liu NJ, vonGizycki H, Gintzler AR. Phospholipase C beta 1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation. Brain Res 2006;1069:47-53.
32. Bianchi E, Norcini M, Smrcka A, Ghelardini C. Supraspinal G beta gamma-dependent stimulation of PLC beta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia. J Neurochem 2009; 111:171-80.
33. Akgul A. Can cardiac fibrosis be prevented? Mast cell inhibition versus anti-chymase activity. Eur J Cardiothorac Surg 2009; 35:553-4.
34. Di Capite J, Parekh AB. CRAC channels and Ca2+ signaling in mast cells. Immunol Rev 2009;231:45-58.
35. Venkatesh P, Mukherjee PK, Kumar SN, Nema NK, Bandyopadhyay A, Fukui H et al. Mast cell stabilization and antihistaminic potentials of Curculigo orchioides rhizomes. J Ethnopharmacol 2009;126:434-6.
36. Yeung CK, Law JK, Sam SW, Ingebrandt S, Lau HY, Rudd JA et al. Modulatory action of potassium channel openers on field potential and histamine release from rat peritoneal mast cells. Can J Physiol Pharmacol 2009;87:624-32.
37. Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, Larabee KS et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009;182: 647-56.
38. Kuehn HS, Beaven MA, Ma HT, Kim MS, Metcalfe DD, Gilfillan AM. Synergistic activation of phospholipases C gamma and C beta: a novel mechanism for PI3K-independent enhancement of Fc epsilon RI-induced mast cell mediator release. Cell Signal 2008;20:625-36.
39. Lessmann E, Leitges M, Huber M. A redundant role for PKC-epsilon in mast cell signaling and effector function. Int Immunol 2006;18:767-73.
40. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006;6:218-30.
41. Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 2009;113:5942-50.
42. Togo K, Suzuki Y, Yoshimaru T, Inoue T, Terui T, Ochiai T et al. Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx. Clin Immunol 2009;131:145-56.
43. Ono E, Taniguchi M, Mita H, Fukutomi Y, Higashi N, Miyazaki E et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009; 39:72-80.
44. Misso NL, Aggarwal S, Thompson PJ, Vally H. Increases in urinary 9alpha, 11 beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma. Int Arch Allergy Immunol 2009;149:127-32.
45. Jiang Y, Borrelli L, Bacskai BJ, Kanaoka Y, Boyce JA. P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells. J Immunol 2009;182:1129-37.
46. Bespalov A, Jongen-Rêlo AL, van Gaalen M, Harich S, Schoemaker H, Gross G. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 2007;320:944-50.